[Berofor alpha 2 (r-HUIFN-alpha 2 arg) and acyclovir in the treatment of dendritic keratitis].

In a double-masked clinical trial a total of 24 patients have so far been treated with recombinant human alpha 2-interferon in combination with Acyclovir (ACV), and 21 patients with a placebo-Acyclovir combination. Both partial and complete healing times were statistically significantly shortened in the r-Hu IFN-alpha 2-AVC group, by 35 and 32 percent respectively. No difference could be demonstrated between the combination of r-Hu IFN-alpha 2 arg and ACV and that of BCL IFN and ACV as far as the therapeutic effect was concerned. R-Hu IFN-alpha 2 drops in combination with Acyclovir ointment were excellently tolerated.

RCT Entities:   Population Interventions Outcomes